Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. (Q46015285)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Oral cyclophosphamide for active scleroderma lung disease: a decision analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Dinesh Khanna

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Daniel E Furst

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Philip J Clements

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Donald P Tashkin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

28 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

published in

Medical Decision Making

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

926-937

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

Severe restrictive lung disease in systemic sclerosis

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Cyclophosphamide versus placebo in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Decision analysis: a progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Primer on medical decision analysis: Part 1--Getting started.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Systemic sclerosis: hypothesis-driven treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Wegener Granulomatosis: An Analysis of 158 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Skin cancer in children and young adults: 28 years' experience from the Northern Region Young Person's Malignant Disease Registry, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X08317015

21 January 2018

Identifiers

DOI

10.1177/0272989X08317015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18443209%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference